Source link : https://www.newshealth.biz/health-news/perioperative-nivolumab-boosts-efs-versus-neoadjuvant-only-nivolumab-in-nsclc/
There was a meaningful reduction in the risk for non-small cell lung cancer (NSCLC) recurrence or death in post-surgical patients treated with perioperative nivolumab (Opdivo) and chemotherapy versus only neoadjuvant nivolumab and chemotherapy, according to an analysis of two phase III trials. The analysis showed an approximate 40% reduction in the risk of disease recurrence […]
Author : News Health
Publish date : 2024-09-09 20:43:35
Copyright for syndicated content belongs to the linked Source.